Development of New Antimicrobial Peptides by Directional Selection

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Rising global antibiotic resistance necessitates novel antimicrobial agents.
• Antimicrobial peptides (AMPs) are promising candidates due to their role in innate immunity.
• Developing enhanced AMPs requires innovative strategies like mutagenesis and screening.

Purpose of the Study:

• To develop novel therapeutic peptides with improved properties.
• To achieve this through mutagenesis of natural AMPs and high-throughput screening.
• To identify variants with enhanced antimicrobial activity and reduced cytotoxicity.

Main Methods:

• Constructed mutant libraries of melittin, cecropin, and Hm-AMP2 using mutagenesis.
• Assessed antimicrobial activity against E. coli and B. subtilis using bacterial growth kinetics and droplet serial dilution assays.
• Determined cytotoxicity in human Expi293F cells and calculated therapeutic index.

Main Results:

• Melittin mutants (MR1P7, MR1P8) exhibited reduced cytotoxicity while maintaining antimicrobial activity.
• Cecropin mutants showed varied efficacy; some gained activity against Gram-positive bacteria.
• Hm-AMP2 mutants demonstrated retained or enhanced efficacy against B. subtilis with low cytotoxicity.

Conclusions:

• The mutagenesis strategy successfully generated peptides with improved therapeutic profiles.
• Identified variants possess reduced toxicity or broader antimicrobial spectrum.
• This approach aids in discovering novel bioactive peptides to combat antibiotic-resistant pathogens.